GCCL and Osong Advanced Medical Industry Promotion Foundation Join Hands for Clinical Research Collaboration

"Enabling Domestic R&D Achievements to Be Realized in Clinical Trials"

Global clinical trial sample analysis institution GCCL announced on March 13 that it has signed a memorandum of understanding (MOU) with the New Drug Development Support Center of Osong Advanced Medical Industry Promotion Foundation (KBIOHealth) to contribute to the advancement of clinical research and the pharmaceutical industry.

Hyejung Han, Director of the New Drug Development Support Center at Osong Advanced Medical Industry Promotion Foundation (left), and Gwankoo Cho, CEO of GCCL, are taking a commemorative photo after signing a Memorandum of Understanding (MOU) to contribute to the advancement of clinical research and the pharmaceutical industry at GCCL in Yongin, Gyeonggi Province on the 12th. Photo by GCCL

Through this MOU, the two organizations plan to collaborate in various fields, including: cooperation to strengthen the connection between the domestic clinical trial sample analysis industry and the new drug development ecosystem; joint research and cooperation on national R&D projects; planning and operating educational programs together to facilitate technical, academic, and professional personnel exchanges; conducting joint marketing activities such as exhibitions, seminars, and promotional activities; and sharing and utilizing domestic and international networks and infrastructure resources.

By combining the public research infrastructure of the New Drug Development Support Center at Osong Advanced Medical Industry Promotion Foundation with GCCL’s experience in clinical trial sample analysis and project execution, the two institutions plan to establish a step-by-step support system so that technologies accumulated during the research and development (R&D) phase can be stably implemented in the clinical trial phase.

Hyejung Han, Head of the New Drug Development Support Center at Osong Advanced Medical Industry Promotion Foundation, stated, "This agreement will serve as an opportunity to promote the practical application of domestic research results and enhance industrial competitiveness by linking new drug development support infrastructure with clinical trial analysis expertise. We will continue to expand collaboration with various industry partners to help vitalize the domestic new drug development ecosystem."

Gwanku Cho, CEO of GCCL, said, "Collaboration with public institutions supporting new drug development is an important opportunity to further strengthen the research foundation of Korea's pharmaceutical and biotechnology industries. We will support domestic R&D achievements so that they can attain global clinical competitiveness."

This content was produced with the assistance of AI translation services.